TY - JOUR
T1 - Antithrombotic Management of Atrial Fibrillation Patients Presenting with Coronary Artery Disease
T2 - A Consensus Document of the Chinese Society of Cardiology
AU - Chinese Society of Cardiology of Chinese Medical Association
AU - Editorial Board of Chinese Journal of Cardiology
AU - Qu, Peng
AU - Liu, Shaowen
AU - Ma, Changsheng
AU - Xue, Yumei
AU - Lei, Xinjun
AU - Han, Yaling
AU - Huang, Lan
AU - Li, Shuyan
AU - Li, Yi
AU - Qi, Xiaoyong
AU - Wang, Zulu
AU - Wu, Shulin
AU - Yuan, Zuyi
AU - Chen, Jiyan
AU - Fu, Guosheng
AU - Gao, Chuanyu
AU - Gao, Wei
AU - Jia, Shaobin
AU - Jiang, Chenyang
AU - Li, Yigang
AU - Liu, Qiming
AU - Liu, Xuebo
AU - Liu, Yuyang
AU - Lou, Dayuan
AU - Lu, Zhibing
AU - Luo, Yongbai
AU - Sun, Yihong
AU - Tang, Yida
AU - Wu, Yongjian
AU - Xu, Yawei
AU - Yang, Lixia
AU - Yang, Xinchun
AU - Yang, Yanmin
AU - Yin, Yuehui
AU - Yuan, Jinqing
AU - Zhang, Ping
AU - Zhang, Ruiyan
AU - Zhang, Shuyang
AU - Zhang, Zheng
N1 - Publisher Copyright:
Copyright © 2021 The Chinese Medical Association, published by Wolters Kluwer Health, Inc.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The coexistence of coronary artery disease (CAD) and atrial fibrillation (AF) is common in clinical practice. Patients with CAD require antiplatelet therapy to reduce the occurrence of myocardial ischemic events. However, patients with AF at high risk of thromboembolism require oral anticoagulants to reduce the occurrence of thromboembolic events such as stroke. In cases where CAD coexists with AF, the combined use of antiplatelet and anticoagulation therapy can effectively reduce the risk of ischemic and thromboembolic events but increase the risk of bleeding at the same time. The optimal antithrombotic regimen in patients with both CAD and AF has been controversial in clinical practice. In recent years, the expert consensuses on antithrombotic therapy in patients with AF presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention have been successively released in Europe and North America, and have been updated in a timely manner. In contrast, the guidelines on antithrombotic therapies in China are lacking. Based on published clinical evidence, this consensus incorporated relevant international and Chinese guidelines, consensuses, and expert recommendations, and addressed the issues encountered in the clinical practice of antithrombotic therapy in patients with AF and different types of CAD. The current guideline is of great significance to guide treatment in patients with both CAD and AF in China.
AB - The coexistence of coronary artery disease (CAD) and atrial fibrillation (AF) is common in clinical practice. Patients with CAD require antiplatelet therapy to reduce the occurrence of myocardial ischemic events. However, patients with AF at high risk of thromboembolism require oral anticoagulants to reduce the occurrence of thromboembolic events such as stroke. In cases where CAD coexists with AF, the combined use of antiplatelet and anticoagulation therapy can effectively reduce the risk of ischemic and thromboembolic events but increase the risk of bleeding at the same time. The optimal antithrombotic regimen in patients with both CAD and AF has been controversial in clinical practice. In recent years, the expert consensuses on antithrombotic therapy in patients with AF presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention have been successively released in Europe and North America, and have been updated in a timely manner. In contrast, the guidelines on antithrombotic therapies in China are lacking. Based on published clinical evidence, this consensus incorporated relevant international and Chinese guidelines, consensuses, and expert recommendations, and addressed the issues encountered in the clinical practice of antithrombotic therapy in patients with AF and different types of CAD. The current guideline is of great significance to guide treatment in patients with both CAD and AF in China.
KW - Antithrombotic management
KW - Atrial fibrillation
KW - Coronary artery disease
UR - https://www.scopus.com/pages/publications/85146455501
U2 - 10.1097/CD9.0000000000000020
DO - 10.1097/CD9.0000000000000020
M3 - 文章
AN - SCOPUS:85146455501
SN - 2096-952X
VL - 1
SP - 15
EP - 28
JO - Cardiology Discovery
JF - Cardiology Discovery
IS - 1
ER -